Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01734512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01734512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2012
Completion date
July 31, 2024
Enrollment
65 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric progressive low-grade gliomas, pediatric recurrent progressive low-grade gliomas